Context Therapeutics INC Form 4 insider transactions

Director Andy Pasternak of Context Therapeutics Inc. acquired 45,000 stock options with an exercise price of $0.576, vesting on June 24, 2027.

Director Stacey Jennifer Evans acquired stock options in Context Therapeutics Inc. (CNTX) on June 24, 2026, as detailed in a recent SEC Form 4 filing.

Director Linda West acquired 45,000 stock options in Context Therapeutics Inc. (CNTX) with an exercise price of $0.576, vesting on June 24, 2027.

Karen L. Smith, a Director at Context Therapeutics Inc., acquired 45,000 stock options on June 24, 2026, as detailed in a Form 4 filing.

Luke Nathaniel Walker, a Director at Context Therapeutics Inc., acquired 45,000 stock options with an exercise price of $0.576.

Philip Kantoff, a Director at Context Therapeutics Inc., acquired 45,000 stock options with an exercise price of $0.576, vesting on June 24, 2027.

Context Therapeutics Inc. reported an insider transaction where its Chief Legal Officer, Alex C. Levit, was granted 270,000 stock options.

Context Therapeutics' Chief Financial Officer, Jennifer Lynn Minai-Azary, was granted 275,000 stock options with an exercise price of $2.32, vesting over four years.

Context Therapeutics' Chief Medical Officer, Karen Deborah Chagin, was granted 290,000 stock options with a $2.32 exercise price, vesting over four years.

Context Therapeutics Inc. CEO Martin A. Lehr was granted 815,000 stock options with an exercise price of $2.32, vesting over four years.

Context Therapeutics Inc. director Andy Pasternak was granted 138,900 stock options with an exercise price of $0.653, aligning his interests with shareholder value.

Context Therapeutics Inc. announced that Director Philip W. Kantoff was granted 123,500 stock options, aligning his interests with shareholder value.

Context Therapeutics Inc. Director Karen L. Smith was granted 123,500 stock options with an exercise price of $0.653, aligning her interests with shareholder value.

Context Therapeutics Inc. director Stacey Jennifer Evans was granted 123,500 stock options with an exercise price of $0.653, vesting on the earlier of June 12, 2026, or the 2026 annual meeting.

Context Therapeutics Inc. director Luke Nathaniel Walker was granted 123,500 stock options with an exercise price of $0.653, aligning his interests with shareholder value.

Context Therapeutics Inc. Director Linda West was granted 123,500 stock options with an exercise price of $0.653, vesting over one year or by the 2026 annual meeting.

Context Therapeutics Inc.'s CEO and Director, Martin A. Lehr, acquired 100,000 shares of common stock through a trust, signaling increased insider confidence in the company.

Alex C. Levit, Chief Legal Officer and Corporate Secretary of Context Therapeutics Inc. (CNTX), has acquired 20,000 shares of common stock, indicating a vote of confidence in the company.

Context Therapeutics Inc.'s Chief Financial Officer, Jennifer Lynn Minai-Azary, acquired 40,010 shares of common stock at a weighted average price of $0.637, increasing her direct beneficial ownership to 80,010 shares.

Context Therapeutics Inc. has granted its Chief Medical Officer, Karen Deborah Chagin, 153,000 stock options with a four-year vesting schedule, aligning executive incentives with long-term company performance.

Jennifer Lynn Minai-Azary, CFO of Context Therapeutics, reports the acquisition of stock options exercisable for 371,800 shares of common stock.

Alex C. Levit, Chief Legal Officer of Context Therapeutics Inc., acquired stock options for 349,900 shares at an exercise price of $0.81 on February 13, 2025.

Claudio Dansky Ullmann, Chief Medical Officer of Context Therapeutics Inc., acquired stock options on February 13, 2025.

Context Therapeutics CEO, Martin A. Lehr, was granted stock options to purchase 802,700 shares of common stock at an exercise price of $0.81 on February 13, 2025.

Andy Pasternak, a director at Context Therapeutics, acquired 20,685 stock options on January 13, 2025.

Karen L. Smith, a director of Context Therapeutics Inc., acquired stock options on September 4, 2024.

Luke Nathaniel Walker, a director of Context Therapeutics Inc., acquired stock options on September 4, 2024.

Claudio Dansky Ullmann, Chief Medical Officer of Context Therapeutics Inc., acquired stock options for 202,170 shares at an exercise price of $2.23 on August 1, 2024.

Director Stacey Jennifer Evans acquired 25,000 stock options in Context Therapeutics Inc. on June 13, 2024.

Director Philip W. Kantoff acquired stock options in Context Therapeutics Inc. on June 13, 2024.